$20.0M
Molten Ventures led the Series B round to support the creation of an artificial intelligence imaging lab.
Qureight
Artificial intelligence imaging platform for lung and heart clinical trials.
$30.5MTotal raised
Cambridge-based Qureight builds artificial intelligence tools to support pharmaceutical companies running clinical trials for respiratory and cardiovascular diseases.
Filed accounts
Cash at bank
Members only
Net current assets
Members only
Total assets less current liabilities
Members only
Net assets
Members only
Shareholders' funds
Members only
Fixed assets
Members only
Cash, assets and headcount from Qureight's latest Companies House filing — with year-on-year movement, free with a Winfred account.
Categories
Founders
MT
Muhunthan Thillai
Co-founder and CEO
Muhunthan is the co-founder and chief executive of Qureight, alongside working as an associate professor at the University of East Anglia and a chest physician at Royal Papworth Hospital. He brings extensive clinical and academic experience from roles across the NHS and Imperial College London.
LinkedInAR
Alessandro Ruggiero
Co-founder
Alessandro combines clinical experience as a consultant cardio-thoracic radiologist at Papworth Hospital with entrepreneurial background as the co-founder and chief operating officer of Qureight.
LinkedInInvestors
- $20.0MMoltenLead
HHHargreave Hale AIM VCTFollow-onXTX VenturesFollow-on
Guinness VenturesFollow-on
MeltwindFollow-on
AscensionFollow-on
- $8.5M
- £1.5M
- £500KCVCMS VenturesLead
Funding history
$8.5M
Hargreave Hale AIM VCT led the financing round to help accelerate the company platform and expand into new disease areas.
£1.5M
Playfair Capital led the seed investment in Qureight, with backing from Meltwind, Ascension, and Cambridge Angels, to accelerate drug development partnerships.
£500K
CMS Ventures has backed the Cambridge clinical analytics start-up in its latest funding round.